SLRX Insider Trading Activity and SEC Form 4 Filings
SLRX insider trading summary
Over the past 12 months, insiders at Salarius Pharmaceuticals, Inc. (SLRX) reported 2 open-market purchases worth $20K by 2 insiders and 2 sales worth $17 by 1 insider on SEC Form 4. Net insider buying was $20K.
Latest SLRX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 30, 2025 | Arnold C Hanish | Director | Sell | $10 (15 @ $0.64) |
| Dec 30, 2025 | Arnold C Hanish | Director | Sell | $8 (12 @ $0.64) |
| Nov 20, 2025 | Arnold C Hanish | Director | Buy | $4K (5,000 @ $0.75) |
| Nov 20, 2025 | Mark J Rosenblum | Exec VP Finance, CFO | Buy | $16K (20,000 @ $0.80) |
| Jun 7, 2022 | Tess Burleson | Director | Buy | $5K (27,700 @ $0.18) |
| Jun 7, 2022 | Jonathan I Lieber | Director | Buy | $7K (37,500 @ $0.19) |
| Jun 6, 2022 | William K. McVicar | Director | Buy | $5K (26,553 @ $0.19) |
| Jun 3, 2022 | Arnold C Hanish | Director | Buy | $5K (28,000 @ $0.18) |
| May 31, 2022 | Mark J Rosenblum | Exec VP Finance, CFO | Buy | $5K (28,000 @ $0.18) |
| May 26, 2022 | David J. Arthur | Chief Executive Officer | Buy | $2K (10,392 @ $0.18) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.